432 related articles for article (PubMed ID: 16984995)
1. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients.
Galland F; Kamenicky P; Affres H; Reznik Y; Pontvert D; Le Bouc Y; Young J; Chanson P
J Clin Endocrinol Metab; 2006 Dec; 91(12):4957-61. PubMed ID: 16984995
[TBL] [Abstract][Full Text] [Related]
2. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
3. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
Akintoye SO; Kelly MH; Brillante B; Cherman N; Turner S; Butman JA; Robey PG; Collins MT
J Clin Endocrinol Metab; 2006 Aug; 91(8):2960-6. PubMed ID: 16720661
[TBL] [Abstract][Full Text] [Related]
4. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
Parkinson C; Burman P; Messig M; Trainer PJ
J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131
[TBL] [Abstract][Full Text] [Related]
5. Difficulties in diagnosis and treatment of acromegaly in a patient with a McCune-Albright syndrome. A case report and a review of literature.
Baszko-Błaszyk D; Slynko J; Liebert W; Sosnowski P; Sowiński J; Waśko R
Neuro Endocrinol Lett; 2010; 31(5):594-6. PubMed ID: 21173751
[TBL] [Abstract][Full Text] [Related]
6. [Acromegaly associated with McCune-Albright syndrome].
Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly and McCune-Albright syndrome.
Salenave S; Boyce AM; Collins MT; Chanson P
J Clin Endocrinol Metab; 2014 Jun; 99(6):1955-69. PubMed ID: 24517150
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
9. McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
Almeida JP; Albuquerque LA; Ferraz CL; Mota I; Gondim J; Ferraz TM
Arq Bras Endocrinol Metabol; 2009 Feb; 53(1):102-6. PubMed ID: 19347192
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
11. [A case of fibrous dysplasia (McCune Albright syndrome) associated with acromegaly].
Chiba Y; Tani N; Tamura N; Nakamura H; Igarashi K; Momotsu T; Tsuda A; Ito S; Shibata A; Tamura T
Nihon Naibunpi Gakkai Zasshi; 1991 Mar; 67(3):239-48. PubMed ID: 2070893
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
13. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
14. McCune-Albright syndrome in adulthood.
Chanson P; Salenave S; Orcel P
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():453-62. PubMed ID: 17982395
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.
Jimenez C; Burman P; Abs R; Clemmons DR; Drake WM; Hutson KR; Messig M; Thorner MO; Trainer PJ; Gagel RF
Eur J Endocrinol; 2008 Nov; 159(5):517-23. PubMed ID: 18708436
[TBL] [Abstract][Full Text] [Related]
17. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
Frohman LA; Bonert V
Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
[TBL] [Abstract][Full Text] [Related]
18. A case of McCune-Albright syndrome associated with Gs alpha mutation in the bone tissue.
Sargin H; Gozu H; Bircan R; Sargin M; Avsar M; Ekinci G; Yayla A; Gulec I; Bozbuga M; Cirakoglu B; Tanakol R
Endocr J; 2006 Feb; 53(1):35-44. PubMed ID: 16543670
[TBL] [Abstract][Full Text] [Related]
19. Lipodystrophy in patients with acromegaly receiving pegvisomant.
Bonert VS; Kennedy L; Petersenn S; Barkan A; Carmichael J; Melmed S
J Clin Endocrinol Metab; 2008 Sep; 93(9):3515-8. PubMed ID: 18611977
[TBL] [Abstract][Full Text] [Related]
20. Pegvisomant: new preparation. A last resort in acromegaly.
Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
